DE60139466D1 - Behandlung von diabetes - Google Patents

Behandlung von diabetes

Info

Publication number
DE60139466D1
DE60139466D1 DE60139466T DE60139466T DE60139466D1 DE 60139466 D1 DE60139466 D1 DE 60139466D1 DE 60139466 T DE60139466 T DE 60139466T DE 60139466 T DE60139466 T DE 60139466T DE 60139466 D1 DE60139466 D1 DE 60139466D1
Authority
DE
Germany
Prior art keywords
diabetes
treatment
delaying
onset
preventing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60139466T
Other languages
English (en)
Inventor
Alessio Fasano
Tammara L Watts
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Maryland at Baltimore
Original Assignee
University of Maryland at Baltimore
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Maryland at Baltimore filed Critical University of Maryland at Baltimore
Application granted granted Critical
Publication of DE60139466D1 publication Critical patent/DE60139466D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/843—Digestive system
    • Y10S530/844—Stomach; intestine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
DE60139466T 2000-05-19 2001-03-21 Behandlung von diabetes Expired - Lifetime DE60139466D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20530500P 2000-05-19 2000-05-19
PCT/US2001/005825 WO2001089551A1 (en) 2000-05-19 2001-03-21 Method of use of peptide antagonists of zonulin to prevent or delay the onset of diabetes

Publications (1)

Publication Number Publication Date
DE60139466D1 true DE60139466D1 (de) 2009-09-17

Family

ID=22761653

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60139466T Expired - Lifetime DE60139466D1 (de) 2000-05-19 2001-03-21 Behandlung von diabetes

Country Status (8)

Country Link
US (6) US7026294B2 (de)
EP (1) EP1282432B1 (de)
JP (3) JP2003534287A (de)
AT (1) ATE438405T1 (de)
AU (1) AU2001249067A1 (de)
CA (1) CA2409771C (de)
DE (1) DE60139466D1 (de)
WO (1) WO2001089551A1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6458925B1 (en) * 1998-08-03 2002-10-01 University Of Maryland, Baltimore Peptide antagonists of zonulin and methods for use of the same
US7026294B2 (en) * 2000-05-19 2006-04-11 University Of Maryland Method of use of peptide antagonists of zonulin to prevent or delay the onset of diabetes
AU2004259705B2 (en) 2003-07-15 2009-04-23 University Of Maryland, Baltimore Agonist polypeptide of receptor for zot and zonulin
US20090176244A1 (en) * 2005-05-13 2009-07-09 Bai Julio Methods and compositions for the diagnosis of crohn's disease
TW200716159A (en) * 2005-06-09 2007-05-01 Univ Maryland Method of use of antagonists of zonulin to prevent the loss of or to regenerate pancreatic cells
CA2638914C (en) 2006-02-09 2014-04-08 Alba Therapeutics Corporation Formulations for a tight junction effector
AU2012203787B2 (en) * 2006-02-09 2014-07-10 Alba Therapeutics Corporation Formulations for a Tight Junction Effector
US20090069247A1 (en) * 2006-10-06 2009-03-12 Blake Paterson Use of tight junction antagonists to treat inflammatory bowel disease
US8034776B2 (en) * 2006-10-26 2011-10-11 Alba Therapeutics Corporation Materials and methods for the treatment of celiac disease
EP2091551B1 (de) * 2006-11-03 2020-01-15 Alba Therapeutics Corporation Verfahren zur behandlung von asthma
AT504214B1 (de) * 2007-01-03 2008-04-15 Bernhard Hans Peter Dipl Ing D Verfahren zur dynamischen, datenabhängigen bestimmung und anwendung von berechtigungen in hierarchischen und relationalen umgebungen
US8728491B2 (en) * 2007-05-07 2014-05-20 Alba Therapeutics Corporation Transcutaneous delivery of therapeutic agents
US20110201543A1 (en) * 2007-06-29 2011-08-18 Blake Paterson Use of tight junction antagonists in the treatment of acute lung injury and acute respiratory distress
US8198233B2 (en) 2007-07-26 2012-06-12 Alba Therapeutics Corporation Synthetic peptides that enhance tight junction permeability
EP2062909A1 (de) 2007-11-21 2009-05-27 SOLVAY (Société Anonyme) Herstellung von Peptiden und Reinigungsverfahren
US9051349B2 (en) 2007-11-21 2015-06-09 Alba Therapeutics Corporation Larazotide acetate compositions
WO2009137436A2 (en) * 2008-05-05 2009-11-12 Alba Therapeutics Corporation Peptide conjugates
WO2009137572A2 (en) 2008-05-06 2009-11-12 Alba Therapeutics Corporation Inhibition of gliadin peptides
EP3579863A4 (de) 2017-02-10 2020-11-11 9 Meters Biopharma, Inc. Zusammensetzungen und verfahren zur behandlung oder prävention von tropischer enteropathie
KR20180107341A (ko) * 2017-03-16 2018-10-02 차의과학대학교 산학협력단 칼륨 경쟁적 위산분비억제제를 유효성분을 함유하는 장 누수 증후군 치료 및 예방용 조성물
WO2019165346A1 (en) 2018-02-23 2019-08-29 Innovate Biopharmaceuticals, Inc. Compounds and methods for treating tight junction permeability
US20210069286A1 (en) * 2018-04-09 2021-03-11 9 Meters Biopharma, Inc. Compositions and methods for treating or preventing hyperglycemia, insulin resistance, and associated organ damage

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5936065A (en) * 1993-12-06 1999-08-10 Cytel Corporation CS-1 peptidomimetics, compositions and methods of using the same
ES2168456T3 (es) * 1995-01-16 2002-06-16 North Sydney Area Health Serv Peptidos que afectan a los linfocitos t.
US5665389A (en) 1995-05-24 1997-09-09 University Of Maryland At Baltimore Oral dosage composition for intestinal delivery and method of treating diabetes
EP0960119B1 (de) * 1996-06-11 2008-09-17 Northern Sydney and Central Coast Area Health Service T zell antigen rezeptor peptide
US5945510A (en) * 1997-05-21 1999-08-31 University Of Maryland, Baltimore Substantially pure zonulin, a physiological modulator of mammalian tight junctions
US6458925B1 (en) * 1998-08-03 2002-10-01 University Of Maryland, Baltimore Peptide antagonists of zonulin and methods for use of the same
US7026294B2 (en) * 2000-05-19 2006-04-11 University Of Maryland Method of use of peptide antagonists of zonulin to prevent or delay the onset of diabetes
US7025294B2 (en) * 2003-05-20 2006-04-11 Carter Day International, Inc. Hammermill with stub shaft rotor apparatus and method
CA2638914C (en) * 2006-02-09 2014-04-08 Alba Therapeutics Corporation Formulations for a tight junction effector
US20090069247A1 (en) * 2006-10-06 2009-03-12 Blake Paterson Use of tight junction antagonists to treat inflammatory bowel disease
US8034776B2 (en) * 2006-10-26 2011-10-11 Alba Therapeutics Corporation Materials and methods for the treatment of celiac disease

Also Published As

Publication number Publication date
US20060128626A1 (en) 2006-06-15
JP2003534287A (ja) 2003-11-18
CA2409771A1 (en) 2001-11-29
US8183211B2 (en) 2012-05-22
EP1282432A1 (de) 2003-02-12
US20100087380A1 (en) 2010-04-08
US20130157943A1 (en) 2013-06-20
US20050065074A1 (en) 2005-03-24
WO2001089551A1 (en) 2001-11-29
US7531512B2 (en) 2009-05-12
JP2011213742A (ja) 2011-10-27
AU2001249067A1 (en) 2001-12-03
US7026294B2 (en) 2006-04-11
US20140128321A1 (en) 2014-05-08
ATE438405T1 (de) 2009-08-15
JP2008074869A (ja) 2008-04-03
CA2409771C (en) 2008-12-02
US20080269136A1 (en) 2008-10-30
EP1282432B1 (de) 2009-08-05
EP1282432A4 (de) 2005-06-08

Similar Documents

Publication Publication Date Title
DE60139466D1 (de) Behandlung von diabetes
DE60023043T2 (de) (S,S)-Reboxetin zur Behandlung von Inkontinenz
DE60124302D1 (de) Thiazolderivate zur behandlung von ppar-lierte krankheiten
DE69817446D1 (de) Behandlung von diabetes
DE69918687D1 (de) 4-phenylpiperidine zur behandlung von prutitischen hauterkrankungen
DE60019556D1 (de) 2-amino-benzoxazinonderivate zur behandlung von fettleibigkeit
DE60114580D1 (de) Verwendung von cyanochinolinen zur behandlung oder inhibierung von dickdarmpolypen
ATE262336T1 (de) Verwendung von 9-desoxy-2',9-alpha-methano-3-oxa- 4,5,6-trinor-3,7-(1',3'-interphenylen)-13,14- dihydroprostaglandin-f1 zur behandlung von peripheren vaskulären erkrankungen
DE60218493D1 (de) Substituierte 7-aza-ä2.2.1übicycloheptane für die behandlung von krankheiten
DE60123238D1 (de) Zusammensetzungen zur behandlung von autoimmunkrankheiten
DE60136477D1 (de) Retinoide zur behandlung von emphysem
DE60132851D1 (de) Arzneimittel zur Vorbeugung, Erleichterung oder Behandlung von Hypertension
DE60204466D1 (de) Integrinhemmer zur behandlung von augenkrankheiten
DE50013843D1 (de) Arzneimittel zur behandlung von darmerkrankungen
ATE372118T1 (de) Die verwendung von rosiglitazon zur behandlung von psychiatrischen erkrankungen.
DE50105735D1 (de) Chlorzoxazon zur behandlung von psoriasis
DE60103685D1 (de) Behandlung von Poriomania
DE60026821D1 (de) Behandlung von bohrspülung
DE60110748D1 (de) Behandlung von fluorkohlenstoff-beschickungen
DE69736180D1 (de) Behandlung von manischen erkrankungen
DE60112768D1 (de) Behandlung von entzündlichen erkrankungen
ATE285764T1 (de) Rivastigmine zur behandlung von augenerkrankungen
DE60124093D1 (de) S-methyl-dihydro-ziprasidon zur Behandlung von Augenerkrankungen.
ATE251167T1 (de) Oxazinocarbazole zur behandlung von cns- erkrankungen
DK0869785T3 (da) 4-Hydroxycoumarin-3-carboxyamider til behandling af ikke-insulinafhængig diabetes mellitus

Legal Events

Date Code Title Description
8364 No opposition during term of opposition